Avadel Pharmaceuticals has patented a modified release formulation of gamma-hydroxybutyrate for treating narcolepsy-related cataplexy or excessive daytime sleepiness. The method involves oral administration of specific dosages with immediate-release and modified-release portions. GlobalData’s report on Avadel Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Avadel Pharmaceuticals, was a key innovation area identified from patents. Avadel Pharmaceuticals's grant share as of May 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for modified release ghb formulation for narcolepsy
A recently granted patent (Publication Number: US11986451B1) discloses a method for treating narcolepsy-related cataplexy or excessive daytime sleepiness in human patients using a gamma-hydroxybutyrate (GHB) formulation. The method involves initiating treatment with a specific dosage of the GHB formulation, which includes both immediate-release (IR) and modified-release (MR) portions. The dosage is then up-titrated in increments equivalent to 1.5 g of sodium oxybate per night, with a maintenance period of at least a week before further adjustments. The treatment protocol emphasizes reaching an effective dosage range of 6 g to 9 g of sodium oxybate per night and ceasing any further up-titration upon achieving the desired effect.
Furthermore, the patent outlines a structured dosing regimen that involves increasing the once per night dosage over several weeks to reach optimal therapeutic levels. The method specifies maintaining each up-titrated dosage for a defined period before progressing to the next level, ensuring a gradual and controlled adjustment process. Additionally, the patent includes provisions for administering a stimulant to the patient and sets limits on the maximum dosage of sodium oxybate that can be administered. The method aims to provide a systematic approach to treating narcolepsy-related symptoms, focusing on individual patient needs and response to the GHB formulation.
To know more about GlobalData’s detailed insights on Avadel Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
